All issues > Volume 28(1); 1985

Original Article

J Korean Pediatr Soc. 1985;28(1):58-67. Published online January 31, 1985.

Captopril in Children with Renovacular Hypertension.

Yong Choi, Hoan Jong Lee, Hee Young Shin, Kwang Wook Ko, Chang Yee Hong

¹Dept, of Pediatrics,College of Medicine,Seoul National University

Abstract

Captopril, a kind of converting enzyme inhibitors, is a promising anti-hypertensive drug, which is developed recently, and studied mainly in adult patients. We administered captopril to 4 children with renovascular hypertension, three of them accompanied Takayasu's arteritis and the remainder had isolated lesion. Three to five times of initial trials were performed on each patient with 12.5 mg of captopril. Blood pressure decreased from 160±19.3/112±ll. 1 mmHg to 124±16.0/86±11.0 with test doses(p<0.01,by paired t-test), the time to nadir ranged from 74 to 95 minutes. With dosage adjustment of captopril and addition of propranolol and/or hydrochlorthiazide, stable blood pressures at normal values were recorded within 1 to 3 weeks. They are on follow-up for 9 to 20 months(mean 13.5 months) with good results. Three of the four patients showed some resistance during early phase of captopril the rapy, though the response to the first dose was remarkable. There was no significant adverse reaction except transient elevation of creatinine in one patient with bilateral renal artery involvement. With the above result, we can conclude that captopril can be safely used for renovascular hypertension resistent to conventional antihypertensive therapy in children either.

Keywords :Takayasu's arteritis;Renovascular hypertension;Captopril;Converting enzymeinhibitor